Apellis Pharmaceuticals, Inc.APLS财报
Nasdaq · 医疗保健 · 药物制剂
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
主要股东
| 股东 | 持股比例 | 股数 | 变动 | 截至 |
|---|---|---|---|---|
| Wellington Management Group LLP | 12.81% | 15.6M | ▼ -1.10pp | 2024-11-08 |
| Avoro Capital Advisors LLC | 9.90% | 13.4M | — | 2024-02-14 |
| EcoR1 Capital, LLC | 9.40% | 11.2M | ▲ +4.00pp | 2024-02-14 |
| The Vanguard Group | 8.06% | 9.6M | — | 2024-02-13 |
| BlackRock, Inc. | 5.10% | 6.2M | 无变化 | 2024-11-08 |
| Deep Track Capital, LP | 4.82% | 6.0M | ▼ -0.18pp | 2024-11-22 |
| T. Rowe Price Investment Management, Inc. | 2.50% | 3.0M | ▼ -2.80pp | 2024-11-14 |
内部人交易
Net 90d: −$8.2K · buys $0 / sells $8.2K时间范围:
类型:
身份:
| 内部人 | 身份 | 类型 | ||||
|---|---|---|---|---|---|---|
| 2026-04-17 | Sullivan Timothy Eugene | Chief Financial Officer | Gift | 11.1K | $0.00 | $0 |
| 2026-04-17 | Sullivan Timothy Eugene | Chief Financial Officer | Gift | 11.1K | $0.00 | $0 |
| 2026-04-06 | O'Brien Stephanie Monaghan | Director | Other | 5.8K | $0.00 | $0 |
| 2026-03-11 | Cedric Francois | Chief Executive Officer | Gift | 64.9K | $0.00 | $0 |
| 2026-03-11 | Cedric Francois | Chief Executive Officer | Gift | 64.9K | $0.00 | $0 |
| 2026-02-27 | Mikael Dolsten | Director | Grant | 14.3K | $0.00 | $0 |
| 2026-02-11 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Sell (open market) | 368 | $22.15 | $8.2K |
| 2026-02-03 | Cedric Francois | Chief Executive Officer | Option exercise | 8.8K | $3.76 | $33.2K |
1–8 of 8